

Docket No. 2026-4276US1**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****RECEIVED**

SEP 16 2002

TECH CENTER 1600/2900

Applicant(s): M. Yangi et al.

Group Art Unit: 1636

Serial No.: 09/662,454

Examiner: Leffers Jr., G.G.

Filed: September 14, 2000

For: CLONED GENOMES OF INFECTIOUS HEPATITIS C VIRUSES AND USES THEREFOR

AMENDMENT FEE TRANSMITTALCommissioner for Patents
Washington, DC 20231

Sir:

Transmitted herewith is an Amendment and Response for the above-identified application.

- ☒ No additional fee is required.
- ☐ The additional fee has been calculated as shown below:

CLAIMS AS AMENDED

	Claims Remaining After Amendment	Highest No. Covered by Previous Payments	Extra	Rate	Additional Fee
Total Claims*	-			\$18.00/ \$9.00	\$
Independent Claims	-			\$84.00/ \$42.00	\$
Multiple Dependent Claims	(If claims added by amendment include Multiple Dependent Claim(s) and there was no Multiple Dependent Claim(s) in application before amendment add \$280.00 to additional fee (\$140.00 for small entity).				\$
TOTAL					\$

*Includes all independent and single dependent claims and all claims referred to in multiple dependent claims. See 37 C.F.R. §1.75(c).

- ☐ Small entity status is or has been claimed.
Reduced Fees Under 37 C.F.R. §1.9(f) paid herewith \$
- ☐ _____ Pages Sequence Listing
- ☐ _____ Computer disk(s) containing substitute Sequence Listing
- ☐ Statement under 37 C.F.R. §1.825(b) that the computer and paper copies of the

substitute Sequence Listing are the same.

- ☐ A check in the amount of \$_____ to cover the filing fee is attached.
- ☐ Charge fee to Deposit Account No. 13-4500, Order No. _____. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required for filing this amendment, including all fees pursuant to 37 CFR §1.17 for its timely consideration, or credit any overpayment to Deposit Account No. 13-4500, Order No. 2026-4276US1. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,
MORGAN & FINNEGAN, L.L.P.

Dated: September 9, 2002

By:



William S. Feiler

Registration No. 26,728

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053
(212) 758-4800 Telephone
(212) 751-6849 Facsimile



RECEIVED

SEP 16 2002

TECH CENTER 1600/2900

PATENT
2026-4276US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : M. Yanagi et al. Group Art Unit: 1636
Serial No. : 09/662,454 Examiner: Leffers Jr., G.G.
Filed : September 14, 2000
For : Cloned Genomes of Infectious Hepatitis C Viruses and Uses
Therefor

Commissioner of Patents
Washington, DC 20231

#8B
Zeta
9-16-02

AMENDMENT AND RESPONSE

Sir:

This Amendment and Response is being filed in reply to the Office Action dated April 9, 2002. Applicants have petitioned herewith, and paid the appropriate fee, for a two month extension of time, extending the time for reply up to, and including, September 9, 2002. Reconsideration is respectfully requested in view of the following:

IN THE CLAIMS:

/ /
Please cancel claim 44 and 54.

Please amend the following claims:

B¹
42. (Twice amended) A pharmaceutical composition comprising a purified and isolated nucleic acid molecule, said nucleic acid molecule encoding a human hepatitis C virus having the amino acid sequence of SEQ ID NO: 3.